OCON Therapeutics, an Israeli pioneer of intrauterine drug-delivery technology for treating severe uterine conditions, has secured $10m in funding to revolutionize drug delivery capabilities. Led by CEO Keren Leshem, the company’s latest funding round was spearheaded by RH Capital, with a significant contribution from Features Capital, Exerte Partners, and Astia Angels. According to OCON Therapeutics
read more..